SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
1-Year Return
18.23%
This Quarter Return
+0.83%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.45B
AUM Growth
+$173M
(+14%)
Cap. Flow
+$220M
Cap. Flow
% of AUM
15.19%
Top 10 Holdings %
Top 10 Hldgs %
47.24%
Holding
102
New
27
Increased
19
Reduced
27
Closed
7
Top Buys
| 1 |
Krystal Biotech
KRYS
|
$66.1M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$34.8M |
| 3 |
UroGen Pharma
URGN
|
$29.9M |
| 4 |
Elevance Health
ELV
|
$27.2M |
| 5 |
UnitedHealth
UNH
|
$26.9M |
Top Sells
| 1 |
TG Therapeutics
TGTX
|
$21.7M |
| 2 |
Insmed
INSM
|
$20.3M |
| 3 |
Hologic
HOLX
|
$18.7M |
| 4 |
Merus
MRUS
|
$18.2M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$18M |
Sector Composition
| 1 | Healthcare | 99.87% |
| 2 | Consumer Staples | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Krystal Biotech
KRYS
$4.35B
| $127M | 8.4% |
922,958
+481,200
| +109% | +$66.1M |
|
2
NovoCure
NVCR
$1.37B
| $123M | 8.14% |
6,904,302
+1,382,888
| +25% | +$24.6M |
|
|
3
TG Therapeutics
TGTX
$5.11B
| $80.8M | 5.35% |
2,243,935
-602,768
| -21% | -$21.7M |
|
4
United Therapeutics
UTHR
$18.1B
| $60.3M | 3.99% |
209,794
+54,400
| +35% | +$15.6M |
|
|
BBNX
5
Beta Bionics, Inc. Common Stock
BBNX
$878M
| $55.6M | 3.68% |
3,820,158
+424,817
| +13% | +$6.19M |
|
6
Grifois
GRFS
$6.89B
| $52M | 3.45% |
5,756,805
-1,333,017
| -19% | -$12.1M |
|
7
STAAR Surgical
STAA
$1.38B
| $50.1M | 3.32% |
2,984,733
+421,840
| +16% | +$7.08M |
|
8
BioMarin Pharmaceuticals
BMRN
$11.1B
| $49.6M | 3.28% |
902,304
-177,000
| -16% | -$9.73M |
|
9
Organogenesis Holdings
ORGO
$634M
| $45.2M | 2.99% |
12,343,351
-135,000
| -1% | -$494K |
|
10
Praxis Precision Medicines
PRAX
$986M
| $40.7M | 2.69% |
966,740
-173,000
| -15% | -$7.27M |
|
11
Celcuity
CELC
$2.36B
| $40.2M | 2.66% |
3,011,818
+437,696
| +17% | +$5.84M |
|
|
12
Alnylam Pharmaceuticals
ALNY
$59.2B
| $34.8M | 2.31% |
+106,750
| New | +$34.8M |
|
13
Terns Pharmaceuticals
TERN
$632M
| $30.5M | 2.02% |
8,167,100
| – | – |
|
|
14
UroGen Pharma
URGN
$873M
| $29.9M | 1.98% |
+2,185,000
| New | +$29.9M |
|
15
Nurix Therapeutics
NRIX
$758M
| $27.6M | 1.83% |
2,422,833
| – | – |
|
|
16
Elevance Health
ELV
$70.6B
| $27.2M | 1.8% |
+70,000
| New | +$27.2M |
|
|
17
UnitedHealth
UNH
$286B
| $26.9M | 1.78% |
+86,250
| New | +$26.9M |
|
18
Neuropace
NPCE
$322M
| $25.8M | 1.71% |
2,312,957
-295,211
| -11% | -$3.29M |
|
19
argenx
ARGX
$45.9B
| $23.6M | 1.57% |
42,876
+13,936
| +48% | +$7.68M |
|
20
Surmodics
SRDX
$463M
| $23.4M | 1.55% |
789,060
| – | – |
|
21
Geron
GERN
$893M
| $22.8M | 1.51% |
16,140,000
+13,740,000
| +573% | +$19.4M |
|
22
Cidara Therapeutics
CDTX
$1.6B
| $22.5M | 1.49% |
+462,811
| New | +$22.5M |
|
23
Evolus
EOLS
$495M
| $19.5M | 1.29% |
2,119,000
+1,039,842
| +96% | +$9.58M |
|
24
Humana
HUM
$37B
| $19.5M | 1.29% |
+79,600
| New | +$19.5M |
|
25
Veracyte
VCYT
$2.55B
| $19.3M | 1.28% |
+715,439
| New | +$19.3M |
|